Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages 20801-20806

  Bakhsheshian, Joshua ^a   Wei, Bih Rong ^a   Chang, Ki Eun ^a   Shukla, Suneet ^a   Ambudkar, Suresh V ^a   Simpson, R Mark ^a   Gottesman, Michael M ^a   Hall, Matthew D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; LUCIFERASE; LUCIFERIN; NILOTINIB;

ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; COMPETITIVE INHIBITION; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84890809612     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312159110     Document Type: Article

References (60)

1. Pardridge WM (2012) Drug transport across the blood-Brain barrier. J Cereb Blood Flow Metab 32(11):1959-1972.
2. Kannan P, et al. (2009) Imaging the function of P-Glycoprotein with radiotracers: Pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368-377.
3. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther 104(1):29-45.
4. Pardridge WM (2001) Crossing the blood-Brain barrier: Are we getting it right Drug Discov Today 6(1):1-2.
5. Uchida Y, et al. (2011) Quantitative targeted absolute proteomics of human bloodbrain barrier transporters and receptors. J Neurochem 117(2):333-345.
6. Xiong H, et al. (2009) ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-Brain barrier for Abeta(1-40) peptides. J Neurosci 29(17):5463-5475.
7. Steeg PS, Camphausen KA, Smith QR (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11(5):352-363.
8. Agarwal S, Hartz AM, Elmquist WF, Bauer B (2011) Breast cancer resistance protein and P-Glycoprotein in brain cancer: Two gatekeepers team up. Curr Pharm Des 17(26): 2793-2802.
9. Vlaming ML, Lagas JS, Schinkel AH (2009) Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 61(1): 14-25.
10. Mairinger S, Erker T, Muller M, Langer O (2011) PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab 12(8):774-792.
11. Kannan P, et al. (2011) Lysosomal trapping of a radiolabeled substrate of P-Glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci USA 108(6): 2593-2598.
12. Kannan P, et al. (2010) N-Desmethyl-Loperamide is selective for P-Glycoprotein among three ATP-Binding cassette transporters at the blood-Brain barrier. Drug Metab Dispos 38(6):917-922.
13. Wanek T, et al. (2012) A novel PET protocol for visualization of breast cancer resistance protein function at the blood-Brain barrier. J Cereb Blood Flow Metab 32(11): 2002-2011.
14. Kusuhara H (2013) Imaging in the study of membrane transporters. Clin Pharmacol Ther 94(1):33-36.
15. Thorne N, Inglese J, Auld DS (2010) Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol 17(6):646-657.
16. Zhang Y, et al. (2007) ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 67(19):9389-9397.
17. Berger F, Paulmurugan R, Bhaumik S, Gambhir SS (2008) Uptake kinetics and biodistribution of 14C-D-Luciferin - a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: Impact on bioluminescence based reporter gene imaging. Eur J Nucl Med Mol Imaging 35(12):2275-2285.
18. Bowie LJ (1978) Synthesis of firefly luciferin and structural analogs. Methods Enzymol 57:15-28.
19. Allen JD, et al. (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1(6):417-425.
20. Bakhsheshian J, et al. (2013) Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos 41(10):1805-1812.
21. Jani M, et al. (2009) Kinetic characterization of sulfasalazine transport by human ATPbinding cassette G2. Biol Pharm Bull 32(3):497-499.
22. Kusch-Poddar M, Drewe J, Fux I, Gutmann H (2005) Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-Brain barrier. Brain Res 1064(1-2):21-31.
23. Zhang Y, et al. (2009) Identification of inhibitors of ABCG2 by a bioluminescence imaging-Based high-Throughput assay. Cancer Res 69(14):5867-5875.
24. Kannan P, et al. (2011) The specific P-Glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci 2(2):82-89.
25. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-Glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-Mediated active efflux. J Pharmacol Exp Ther 334(1):147-155.
26. Ozvegy-Laczka C, et al. (2004) High-Affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65(6):1485-1495.
27. Shepard RL, Cao J, Starling JJ, Dantzig AH (2003) Modulation of P-Glycoprotein but not MRP1-Or BCRP-Mediated drug resistance by LY335979. Int J Cancer 103(1): 121-125.
28. Bao X, et al. (2012) [C]Rhodamine-123: Synthesis and biodistribution in rodents. Nucl Med Biol 39(8):1128-1136.
29. Zhu L, et al. (2004) Non-Invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett 367(2):210-212.
30. Bignami A, Eng LF, Dahl D, Uyeda CT (1972) Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res 43(2):429-435.
31. Cho W, Hagemann TL, Johnson DA, Johnson JA, Messing A (2009) Dual transgenic reporter mice as a tool for monitoring expression of glial fibrillary acidic protein. J Neurochem 110(1):343-351.
32. Muzi M, et al. (2012) Quantitative assessment of dynamic PET imaging data in cancer imaging. Magn Reson Imaging 30(9):1203-1215.
33. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59(17):4237-4241.
34. Robey RW, et al. (2003) Mutations at amino-Acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89(10):1971-1978.
35. Glavinas H, et al. (2007) ABCG2 (breast cancer resistance protein/mitoxantrone resistance-Associated protein) ATPase assay: A useful tool to detect drug-Transporter interactions. Drug Metab Dispos 35(9):1533-1542.
36. Wanek T, Mairinger S, Langer O (2013) Radioligands targeting Pglycoprotein and other drug efflux proteins at the blood-Brain barrier. J Labelled Comp Radiopharm 56(3-4):68-77.
37. Sun W, et al. (2013) Gefitinib enhances the efficacy of photodynamic therapy using 5-Aminolevulinic acid in malignant brain tumor cells. Photodiagn Photodyn Ther 10(1): 42-50.
38. Sane R, Agarwal S, Mittapalli RK, Elmquist WF (2013) Saturable active efflux by pglycoprotein and breast cancer resistance protein at the blood-Brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther 345(1):111-124.
39. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36(6): 995-1002.
40. Takashima T, et al. (2013) Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807. J Nucl Med 54(2): 267-276.
41. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y (2010) Kinetic analysis of the cooperation of P-Glycoprotein (P-Gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333(3):788-796.
42. Zhao R, et al. (2009) Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-Brain barrier. Drug Metab Dispos 37(6):1251-1258.
43. Kodaira H, et al. (2011) Quantitative evaluation of the impact of active efflux by pglycoprotein and breast cancer resistance protein at the blood-Brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 339(3):935-944.
44. Bauer M, et al. (2012) Pgp-Mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-Brain barrier: A comparison with rat data. Clin Pharmacol Ther 91(2):227-233.
45. Kalvass JC, et al.; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-Brain barrier is unlikely: The ITC evidence-Based position. Clin Pharmacol Ther 94(1):80-94.
46. Neuwelt EA, et al. (1980) Reversible osmotic blood-Brain barrier disruption in humans: Implications for the chemotherapy of malignant brain tumors. Neurosurgery 7(1): 44-52.
47. Aswendt M, Adamczak J, Couillard-Despres S, Hoehn M (2013) Boosting bioluminescence neuroimaging: An optimized protocol for brain studies. PLoS ONE 8(2): E55662.
48. Watts JC, et al. (2011) Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 108(6):2528-2533.
49. Tamgüney G, et al. (2009) Measuring prions by bioluminescence imaging. Proc Natl Acad Sci USA 106(35):15002-15006.
50. Luo J, Ho P, Steinman L, Wyss-Coray T (2008) Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease. J Neuroinflammation 5:6.
51. Lee J, Borboa AK, Baird A, Eliceiri BP (2011) Non-Invasive quantification of brain tumor-Induced astrogliosis. BMC Neurosci 12:9.
52. Tran DK, Jensen RL (2013) Treatment-Related brain tumor imaging changes: So-Called pseudoprogression vs. tumor progression: Review and future research opportunities. Surg Neurol Int 4(suppl 3):S129-S135.
53. Willis CL (2011) Glia-Induced reversible disruption of blood-Brain barrier integrity and neuropathological response of the neurovascular unit. Toxicol Pathol 39(1):172-185.
54. Engelhardt B, Sorokin L (2009) The blood-Brain and the blood-Cerebrospinal fluid barriers: Function and dysfunction. Semin Immunopathol 31(4):497-511.
55. Pardridge WM (2005) The blood-Brain barrier: Bottleneck in brain drug development. NeuroRx 2(1):3-14.
56. Kirk R (2012) Clinical trials: New options for melanoma Nat Rev Clin Oncol 9(7):368.
57. Wang JQ, et al. (2006) PET imaging and optical imaging with D-Luciferin [11C]methyl ester and D-Luciferin [11C]methyl ether of luciferase gene expression in tumor xenografts of living mice. Bioorg Med Chem Lett 16(2):331-337.
58. Mahringer A, Fricker G (2010) BCRP at the blood-Brain barrier: Genomic regulation by 17â-Estradiol. Mol Pharm 7(5):1835-1847.
59. Kadurugamuwa JL, et al. (2005) Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response. Infect Immun 73(12):7836-7843.
60. Kanzaki S, et al. (2012) Novel in vivo imaging analysis of an inner ear drug delivery system in mice: Comparison of inner ear drug concentrations over time after transtympanic and systemic injections. PLoS ONE 7(12):e48480.